Remedy Plan Therapeutics

Executive Summary

Remedy Plan Therapeutics is a San Diego-based private biotechnology company pioneering first-in-class small molecule inhibitors of NAMPT, an enzyme critical for tumor metabolism and cancer stem cell maintenance. Their lead candidate, RPT1G, is a hyperbolic NAMPT inhibitor designed to circumvent the on-target toxicities that have historically hindered this target class. By disrupting NAD+ synthesis, RPT1G aims to halt tumor growth and prevent metastasis through selective targeting of cancer stem cells. The company has advanced RPT1G into Phase 2 clinical trials, positioning it as a potential best-in-class therapy for multiple solid tumors. With a novel mechanism and a focus on overcoming prior limitations, Remedy Plan represents a high-risk, high-reward opportunity in oncology. The company's progress through Phase 2 suggests validation of their differentiated approach, though clinical data and safety profiles remain key milestones to watch.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 interim data readout for RPT1G in solid tumors40% success
• TBDPotential partnering or licensing deal for RPT1G30% success
• Q3 2026Initiation of Phase 2 expansion cohorts in additional indications50% success